These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1379921)

  • 1. Efficacy of terazosin in patients with benign prostatic hyperplasia.
    Matzkin H; Soloway MS; Rangel MC; Laddu A
    Eur Urol; 1992; 21(2):126-30. PubMed ID: 1379921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Sunshine H
    J Urol; 1990 Dec; 144(6):1393-7; discussion 1397-8. PubMed ID: 1700152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
    Woods AL
    Mil Med; 1992 Jul; 157(7):361-4. PubMed ID: 1382248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
    Lepor H; Meretyk S; Knapp-Maloney G
    J Urol; 1992 Jun; 147(6):1554-7. PubMed ID: 1375659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
    Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
    Brawer MK; Adams G; Epstein H
    Arch Fam Med; 1993 Sep; 2(9):929-35. PubMed ID: 7509243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks IR; MacDonald R
    Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia.
    Horiuchi K; Tsuboi N; Suzuki Y; Yoshida K; Akimoto M
    J Nippon Med Sch; 2001 Apr; 68(2):181-5. PubMed ID: 11301364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients.
    Okada H; Kamidono S; Yoshioka T; Okuyama A; Ozono S; Hirao Y; Okajima E; Yamamoto K; Kishimoto T; Park Y; Kurita T
    BJU Int; 2000 Apr; 85(6):676-81. PubMed ID: 10759664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks I; Macdonald R
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
    Mudiyala R; Ahmed A
    J Am Geriatr Soc; 2003 Mar; 51(3):424-6. PubMed ID: 12588590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
    Lee E; Lee C
    Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
    Lepor H
    Urology; 1995 Mar; 45(3):406-13. PubMed ID: 7533452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
    Dunzendorfer U
    Arzneimittelforschung; 1989 Oct; 39(10):1289-91. PubMed ID: 2482025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up.
    Fabricius PG; Hannaford JM
    Br J Urol; 1992 Nov; 70 Suppl 1():10-6. PubMed ID: 1281726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
    Lepor H; Machi G
    Prostate; 1992; 20(2):89-95. PubMed ID: 1372430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.